Lexaria Bioscience (LEXX) Announces Plans for Growth

Strategic growth plan execution underway.

Lexaria Bioscience Corp. (NASDAQ: LEXX)(NASDAQ: LEXXW) a global innovator in drug delivery platforms announces plans for strategic growth.

"Lexaria has certain initiatives underway that are increasing confidence in our medium-term and longer-term strategies," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "As a result of the success we are experiencing and the continued success we are anticipating, we will be implementing a number of strategic steps in the weeks and months to come."

Lexaria will be expanding its management team this summer as it prepares for the greater workload of multiple projects and initiatives. The first step is appointing Nelson Cabatuan as our consulting Chief Strategic Financial Advisor, in order to maximize his skills in the fields of corporate finance and strategic industry relationships and opportunities. Nelson is resigning from his current role as Chief Financial Officer (CFO) in order to better focus on the strategic opportunities afforded to the Company outside of typical accounting tasks. Our new CFO will be appointed and announced in due course.

The Company is also in the conceptual design stages of additional R&D projects related to additional GLP-1 molecules of interest, beyond those previously disclosed. Announcements about additional R&D studies may be made over the next several months. Finally, Lexaria is closely examining its Phase 1b hypertension study, that has already received clearance to proceed from the FDA, for more concrete steps to launch that study, subject to funding, as soon as possible.

You May Also Be Interested In

• Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
• Agenus to present BOT+BAL cancer data at ESMO 2026 congress
• U.S. tsunami warning system: tsunami threat after magnitude 7.4 earthquake near the coast of Chiapas Mexico